(S)-Adenosine, cyclic 3′,5′-(hydrogenphosphorothioate) triethylammonium (CAS 71774-13-5)

(S)-Adenosine, cyclic 3',5'-(hydrogenphosphorothioate) triethylammonium is an activator of cAMP-dependent protein kinase (PKA) (cAMP agonist). Considerably higher resistance against cyclic nucleotide-dependent phosphodiesterases as compared to N6,O2'-dibutyryladenosine 3',5'-cyclic monophosphate (dibutyryl-cAMP) or 8-bromoadenosine-3',5'-cyclic monophosphate (8-Br-cAMP). There are no metabolic side effects and it is membrane permeable in many biological systems. Also suggested as an activator of Epac (cAMP-regulated guanine nucleotide exchange factor).

References

Probing the cyclic nucleotide binding sites of cAMP-dependent protein kinases I and II with analogs of adenosine 3',5'-cyclic phosphorothioates: W.R.G. Dostmann, et al.; J. Biol. Chem. 265, 10484 (1990) Cyclic AMP antagonist Rp-cAMPS inhibits amylase exocytosis from saponin- permeabilized parotid acini: T. Takuma & T. Ichida; J. Biochem. 110, 292 (1991) Second messenger signaling in the regulation of cytosolic pH and DNA synthesis by parathyroid hormone (PTH) and PTH-related peptide in osteoblastic osteosarcoma cells: role of Na+/H+ exchange: T. Sugimoto, et al.; J. Cell Physiol. 152, 28 (1992) The activation of cAMP-dependent protein kinase is directly linked to the stimulation of bone resorption by parathyroid hormone: H. Kaji, et al.; BBRC 182, 1356 (1992) Intracellular cyclic AMP not calcium, determines the direction of vesicle movement in melanophores: direct measurement by fluorescence ratio imaging: P.J. Sammak, et al.; J. Cell. Biol. 117, 57 (1992) Effects of activators and inhibitors of protein kinase A on increases in quantal size at the frog neuromuscular junction: W. Van Der Kloot & D.D. Branisteanu; Pfluegers Arch. 420, 336 (1992)